When the scientific superpower baton passes from the United States to China, there won't be a ceremony. There won't be a press conference. A small group of specialists who study the practice of science itself — metascientists — will likely be the first to register the moment, quietly, in the data.
That moment, according to new analysis published by Nature, may arrive as soon as 2028 or 2029.
The forecast, produced by researchers at the Frontiers in Science and Innovation Policy program at the University of California, San Diego, projects that China's government spending on research and development will surpass that of the United States within two to three years. The U.S. has held the global lead in R&D investment since the end of World War II. That eight-decade reign appears to be ending.
The Numbers Tell the Story
The trajectory is stark. Between 2013 and 2023, China's government spending on R&D increased by 90%, reaching $133 billion (purchasing-power-adjusted), according to OECD data cited in the Nature analysis. Over the same decade, U.S. government R&D spending grew by just 12%, reaching $155 billion. The gap is narrowing fast.
China also announced in early March 2026 that its total annual research spending — from all sources — will grow by at least 7% per year through 2030 as part of the country's new five-year plan, according to Nature. Yutao Sun, a specialist in innovation policy at Dalian University of Technology, told Nature that actual government spending could increase even more, potentially accelerating the crossover date.
"I think the earliest likely is 2028, plus or minus one year," Robert Conn, who co-leads the FSIP program and specializes in research policy, told Nature. "It could be next year, could be 2029."
Total R&D spending tells only part of the story. In 1991, China spent $13 billion on R&D. Today, its annual spending from all sources exceeds $800 billion — second only to the United States — according to The Atlantic's analysis of the Chinese data.
The American Retreat
The FSIP analysis is, in one important sense, conservative: it assumes U.S. research spending remains flat. That may be optimistic given current policy direction.
Since President Trump took office in January 2025, the administration has canceled research grants in bulk, suspended entire lines of investigation, and defunded major research programs. In August 2025, the Department of Health and Human Services canceled $500 million in mRNA vaccine research — less than two years after American scientists won a Nobel Prize for pioneering that technology — according to The Atlantic.
More than 10,000 science PhD holders have left the federal workforce, according to one group's estimate cited by The Atlantic. Money has been withheld from frontline researchers in computer science, biomedicine, and hundreds of other fields. One historian of science described the situation to The Atlantic in July as "an unparalleled destruction from within."
The FSIP team told Nature that Congress has provided some resistance to the White House's proposed cuts — but the team expects that over the coming years, U.S. funding for fundamental research agencies like the National Science Foundation and National Institutes of Health will decline in real terms, as the White House's pressure ultimately prevails.
This puts China on track to surpass the U.S. in fundamental research spending "within a decade," according to Conn. Fundamental research — the basic science with no immediate commercial application — is the "seed corn" of future innovation. It is what becomes the breakthrough cancer drug, the new materials technology, the computing paradigm, a decade or more down the line.
Pipeline: Who's Training the Scientists?
Beyond spending, the raw pipeline of scientific talent has shifted dramatically.
China's universities are producing approximately twice as many STEM degrees as their U.S. counterparts, according to The Atlantic. By 2025, Chinese universities were projected to award approximately 77,000 STEM PhD graduates per year, compared with approximately 40,000 in the United States, according to projections from the Center for Security and Emerging Technology at Georgetown University published in 2021.
China's population is four times the size of America's, and its culture is described as "unabashedly pro-science" even relative to other developed nations, according to The Atlantic's analysis. The combination of scale, state investment, and cultural emphasis on technical education creates a talent pipeline that has no equivalent in the West.
Quality, Not Just Quantity
The early critique of China's research surge was about quality: critics pointed to cash-for-publications programs at some universities that incentivized volume over rigor, producing waves of low-quality papers. The Chinese government subsequently ordered universities to end those practices. Salary and promotion factors for professors were restructured to reward quality, not just output.
The data suggests it worked. China's share of the world's most widely cited scientific papers has grown, Caroline Wagner, a professor at Ohio State University who studies scientific policy, told The Atlantic. In 2023, Chinese scientists produced 58,000 of the world's roughly 190,000 most influential publications, according to Wagner. Their contribution was second only to the United States.
In the 145 natural-science and health-science journals tracked by the Nature Index, China's contribution is on track to be double that of the United States by the end of 2026, according to Nature's own analysis.
A 2024 analysis of international research collaborations, using machine learning to identify lead authors of nearly 6 million scientific teams, found that among U.S.-China collaborations, the share led by scientists affiliated with Chinese institutions grew from 30% in 2010 to 45% in 2023, according to The Atlantic. The researchers projected that China will achieve parity with the U.S. in team leadership by 2027 or 2028 at the latest.
The Applied Edge
In the applied sciences — where basic research becomes real-world technology — China has already moved from challenger to leader in several key industries.
Advances in chemistry and materials science have allowed China to catch up with or surpass the U.S. in the design and manufacture of advanced batteries, electric vehicles, and solar cells — which The Atlantic's Ross Andersen described as "key technologies for the 21st century." Chinese electric vehicles now dominate global sales. Chinese solar panels account for the overwhelming majority of global production capacity. Chinese battery manufacturers control an estimated 75% to 80% of global lithium-ion battery production, according to industry data.
Yian Yin, a professor of information science at Cornell University who contributed to the research discussed by The Atlantic, framed the distinction carefully: "We don't just want papers. We want papers that turn into real theoretical insights or technologies." China's rise in the citation metrics is meaningful, he said, but what matters more is whether the research creates lasting knowledge and deployable technology. In the applied sciences, that bar is increasingly being cleared.
The Lag Problem
Measuring scientific leadership is inherently backward-looking. Papers published today reflect research done one to two years ago. The citation rates that indicate influence peak years after publication. Nobel Prizes are frequently awarded decades after the underlying discovery.
China's one and only Nobel Prize in the sciences for work done in China — Tu Youyou's 2015 prize in medicine for the discovery of artemisinin — reflects work completed in the 1970s. The breakthrough research being done in China today won't show up in Nobel announcements for a generation.
But the trajectory indicators that can be measured now — spending growth, PhD production, citation rates, research leadership in international collaborations — all point in the same direction.
What This Means
Scientific leadership has consequences that extend far beyond academia. The nations that pioneer the fundamental understanding of biology, chemistry, materials, and computation are the nations that develop the breakthrough medicines, the advanced weapons, the dominant industries, and the geopolitical leverage that comes from technological primacy.
The United States maintained that leadership for roughly 80 years by combining generous federal funding, world-class universities, an open immigration system that attracted global talent, and a culture of academic freedom. Several of those pillars are now under pressure simultaneously: federal funding is being cut, immigration restrictions are rising, and political friction is increasing in the research environment.
China, by contrast, is simultaneously expanding its funding, growing its talent base, and maintaining long-term institutional continuity in scientific investment. Its government's five-year science plan provides a stability of funding commitment that the American system — subject to annual appropriations fights and political turbulence — increasingly cannot match.
The crossover, when it comes, will not be announced. But its effects will be felt for decades.